【摘要】 目的评价吡柔比星(THP)、丝裂霉素C(MMC)40 mg、丝裂霉素C 10 mg膀胱灌注预防膀胱肿瘤术后复发的疗效和安全性。方法将近期收治的86例膀胱肿瘤术后患者分为3组,分别接受THP、MMC治疗,随访12~20个月。结果 THP组26例,复发2例,复发率7.7％;MMC组26例,复发3例,复发率11.5％;MMC组31例,复发11例,复发率35.5％。THP组与MMC组相比差异无显著性(P>0.05),而THP组和40mgMMC组与MMC组相比则差异有显著性(P<0.05)。结论吡柔比星和丝裂霉素C 40 mg膀胱灌注预防膀胱肿瘤术后复发效果满意,优于丝裂霉素C 10 mg膀胱灌注。更多还原

【Abstract】 Objective To evaluate effectiveness and safety of instilling pirarubicin(THP), mitomycin C (MMC) 40 mg and MMC 10 mg intravesically after operation of bladder carcinoma in prevention of tumor recurrence . Methods Eighty-six patients with bladder cancer after operation were randomly divided into 3 groups to receive intravesical treatment with THP,MMC 40 mg and MMC 10 mg respectively. All these patients were followed up for 12-20 months.Result Recurrence rate in patients treated with pirarubicin was 7.7%(2/26) ,MMC 40 mg was 11.5%(3/26) and MMC 10 mg was 35.5%(11/31) .Conclusions The rates of recurrence in group treated with pirarubicin and mitomycin C 40 mg were lower than that in mitomycin 10 mg group.更多还原